News Center

Home page

Peak Report

News reports

Pro 2014-033 (Supplementary Announcement of Jianfeng Group's First Extraordinary Shareholders' Meeting in 2014)

Release time:

2020-08-05

Securities Code: 600668 Securities Abbreviation: Jianfeng Group Announcement No.: 2014-033

Bond Abbreviation: 13 Jianfeng 01 Bond Code: 122227

Zhejiang Jianfeng Group Co., Ltd.

Supplementary Announcement of the First Extraordinary General Meeting of Shareholders in 2014

The Board of Directors and all directors of the Company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and assumes individual and joint responsibility for the truthfulness, accuracy and completeness of its contents .

According to Article 31 of the Rules of the General Meeting of Shareholders of Listed Companies (revised in 2014), when the general meeting of shareholders considers major matters affecting the interests of small and medium investors, The votes of small and medium investors shall be counted separately. The results of the separate vote count shall be disclosed publicly in a timely manner. The voting results of the company's small and medium shareholders (shareholders holding less than 5% of the company's total share capital) are now additionally disclosed as follows:

The 157 of small and medium shareholders and proxies attending the company's first extraordinary general meeting in 2014, representing 12750148 shares, accounting for 3.71 of the company's total share capital. The voting results of minority shareholders and proxies are as follows:

1. Jiang Xiaomeng was elected as a director of the ninth board of directors;

Agree Number of Shares	Agree Ratio	Oppose Number of Shares	Oppose Ratio	Abstention Number of Shares	Abstention Ratio
8662671	67.94%	3972376	31.16%	115101	0.90

2. Du Zihong was elected as a director of the 9th Board of Directors;

number of shares	number of shares	number of shares	number of shares	number of shares	number of shares
9397871	73.71%	906556	7.11%	2445721	19.18%

3. Yu Jianhong was elected as a director of the ninth board of directors;

number of shares	number of shares	number of shares	number of shares	number of shares	number of shares
8652071	67.86%	1897556	14.88%	2200521	17.26

4. Huang Sujian was elected as a director of the ninth board of directors;

number of shares	number of shares	number of shares	number of shares	number of shares	number of shares
9554027	74.93%	605700	4.75%	2590421	20.32%

5. Wu Guanghui was elected as a director of the 9th board of directors;

number of shares	number of shares	number of shares	number of shares	number of shares	number of shares
9532627	74.76%	605700	4.75%	2611821	20.48%

6, Zhu Linming was elected as a director of the ninth board of directors;

number of shares	number of shares	number of shares	number of shares	number of shares	number of shares
9532627	74.76%	605700	4.75%	2611821	20.48%

7. Zhang Yuyou was elected as an independent director of the 9th board of directors;

More information

Monitoring Report of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project

2020

07-30

Monitoring Report of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project

2020

07-31

Monitoring Report of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project

2020

07-31

Daye Jianfeng Cement Co., Ltd. Kiln End Flue Gas Desulfurization Project Completion Environmental Protection Acceptance Publicity

Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution

2020

07-31

Spike New Drug Approved for Registration

On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)

2020

07-31

Spike New Drug Approved for Registration

2020

07-31

< 1...30 31 32...61 > 跳转到页